TAO Synergies (TAOX) Net Income towards Common Stockholders (2019 - 2026)
TAO Synergies' (TAOX) quarterly Net Income towards Common Stockholders came in at -$13.7 million in Q2 2026, up 22.48% on a YoY basis from -$11.2 million in Q2 2025, and down 509.51% quarter-over-quarter from $3.3 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$13.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 22.48% year-over-year to -$13.7 million; the trailing twelve-month figure through Jun 2026 stood at -$22.1 million (up 24.32% YoY), and the FY2025 full-year result was -$29.1 million, down 114.45% from the prior year.
- Net Income towards Common Stockholders fell to -$13.7 million in Q2 2026 per TAOX's latest filing, from $3.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $4.4 million in Q4 2022 and bottomed at -$17.6 million in Q2 2025.
- Historically, Net Income towards Common Stockholders has averaged -$4.0 million across 5 years, with a median of -$3.2 million in 2022.
- The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders plunged 1573.58% in 2024, then jumped 1887.19% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at $4.4 million in 2022, then tumbled by 128.16% to -$1.2 million in 2023, then sank by 360.0% to -$5.7 million in 2024, then tumbled by 37.43% to -$7.8 million in 2025, then plunged by 75.73% to -$13.7 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$13.7 million, $3.3 million, and -$7.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -290.61 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - | -13.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.66 Mn |
| Mar 31, 2026 | 3.34 Mn |
| Dec 31, 2025 | -7.77 Mn |
| Sep 30, 2025 | -3.97 Mn |
| Jun 30, 2025 | -17.62 Mn |
| Mar 31, 2025 | 167,836.00 |
| Dec 31, 2024 | -5.66 Mn |
| Sep 30, 2024 | -6.05 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -425,158.00 |
| Dec 31, 2023 | -1.23 Mn |
| Sep 30, 2023 | -361,425.00 |
| Jun 30, 2023 | -10.21 Mn |
| Mar 31, 2023 | -1.98 Mn |
| Dec 31, 2022 | 4.37 Mn |
| Sep 30, 2022 | -3.03 Mn |
| Jun 30, 2022 | -3.75 Mn |
| Mar 31, 2022 | -3.28 Mn |
| Dec 31, 2021 | -4.24 Mn |
| Sep 30, 2021 | -2.93 Mn |